Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:DYAX
- CUSIP: 26746E10
- Web: www.dyax.com
Average Prices:- 50 Day Moving Avg: $37.73
- 200 Day Moving Avg: $29.05
- 52 Week Range: $14.06 - $38.56
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -274.36
- P/E Growth: 0.00
Profitability:- Net Margins: -47.32%
- Return on Equity: -14.86%
- Return on Assets: -12.09%
Misc:- Average Volume: 3.62 million shs.
Frequently Asked Questions for Dyax Corp. (NASDAQ:DYAX)
What is Dyax Corp.'s stock symbol?
Dyax Corp. trades on the NASDAQ under the ticker symbol "DYAX."
How were Dyax Corp.'s earnings last quarter?
Dyax Corp. (NASDAQ:DYAX) issued its earnings results on Wednesday, October, 28th. The company reported ($0.08) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.08). The business earned $24.70 million during the quarter, compared to analysts' expectations of $24.96 million. Dyax Corp. had a negative net margin of 47.32% and a negative return on equity of 14.86%. The company's quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.01) earnings per share. View Dyax Corp.'s Earnings History.
Who are some of Dyax Corp.'s key competitors?
Some companies that are related to Dyax Corp. include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT) and GW Pharmaceuticals PLC (GWPH).
How do I buy Dyax Corp. stock?
Shares of Dyax Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dyax Corp.'s stock price today?
One share of Dyax Corp. stock can currently be purchased for approximately $38.41.
MarketBeat Community Rating for Dyax Corp. (NASDAQ DYAX)MarketBeat's community ratings are surveys of what our community members think about Dyax Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Dyax Corp. (NASDAQ:DYAX)Earnings History by Quarter for Dyax Corp. (NASDAQ DYAX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/28/2015 | Q315 | ($0.08) | ($0.08) | $24.96 million | $24.70 million | View | N/A |  |
| 7/29/2015 | Q215 | ($0.04) | ($0.06) | $23.40 million | $264.00 million | View | Listen | |
| 4/29/2015 | Q115 | ($0.05) | ($0.05) | $21.79 million | $20.40 million | View | N/A | |
| 2/24/2015 | Q414 | ($0.04) | ($0.02) | $19.90 million | $26.00 million | View | N/A | |
| 10/28/2014 | Q314 | ($0.06) | ($0.01) | $15.70 million | $22.00 million | View | N/A | |
| 7/29/2014 | Q214 | ($0.05) | ($0.02) | $14.13 million | $19.59 million | View | N/A | |
| 4/30/2014 | Q1 2014 | ($0.05) | ($0.05) | $13.65 million | $14.12 million | View | N/A | |
| 2/28/2014 | Q413 | ($0.04) | ($0.02) | $15.84 million | $16.90 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Dyax Corp. (NASDAQ:DYAX)Current Year EPS Consensus Estimate: $-0.26 EPS
Next Year EPS Consensus Estimate: $-0.14 EPS
Dividend History for Dyax Corp. (NASDAQ:DYAX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Dyax Corp. (NASDAQ:DYAX)Insider Trades by Quarter for Dyax Corp. (NASDAQ:DYAX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/10/2015 | Thomas L Kempner | Director | Sell | 6,000 | $22.47 | $134,820.00 | |
| 8/28/2015 | Thomas L Kempner | Director | Sell | 17,947 | $23.83 | $427,677.01 | |
| 8/18/2015 | Thomas L Kempner | Director | Sell | 18,035 | $23.83 | $429,774.05 | |
| 8/13/2015 | Thomas L Kempner | Director | Sell | 4,848 | $23.81 | $115,430.88 | |
| 7/20/2015 | Henry E Blair | Director | Sell | 50,000 | $27.05 | $1,352,500.00 | |
| 6/8/2015 | David J Mclachlan | Director | Sell | 75,000 | $25.63 | $1,922,250.00 | |
| 3/6/2015 | Andrew D Ashe | EVP | Sell | 2,400 | $15.50 | $37,200.00 | |
| 3/5/2015 | Burt A Adelman | CMO | Sell | 9,375 | $15.66 | $146,812.50 | |
| 3/5/2015 | George V Migausky | CFO | Sell | 5,000 | $15.86 | $79,300.00 | |
| 3/5/2015 | Gustav Christensen | CEO | Sell | 6,250 | $15.86 | $99,125.00 | |
| 2/26/2015 | Andrew D Ashe | EVP | Sell | 1,500 | $15.34 | $23,010.00 | |
| 1/2/2015 | Burt A Adelman | CMO | Sell | 75,000 | $14.05 | $1,053,750.00 | |
| 12/5/2014 | Thomas L Kempner | Director | Sell | 14,764 | $13.79 | $203,595.56 | |
| 11/21/2014 | Thomas L Kempner | Director | Sell | 100,000 | $13.20 | $1,320,000.00 | |
| 9/12/2014 | Thomas L Kempner | Director | Sell | 12,400 | $11.00 | $136,400.00 | |
| 8/26/2014 | Thomas L Kempner | Director | Sell | 37,000 | $10.39 | $384,430.00 | |
| 8/19/2014 | Thomas L Kempner | Director | Sell | 113,755 | $9.67 | $1,100,010.85 | |
| 8/7/2014 | Thomas L Kempner | Director | Sell | 33,190 | $9.25 | $307,007.50 | |
| 6/13/2014 | George V Migausky | CFO | Sell | 16,000 | $8.26 | $132,160.00 | |
| 3/5/2014 | Henry Blair | Director | Sell | 150,000 | $10.46 | $1,569,000.00 | |
| 3/3/2014 | Andrew Ashe | EVP | Sell | 30,000 | $10.00 | $300,000.00 | |
| 3/3/2014 | Burt Adelman | CMO | Sell | 55,000 | $9.68 | $532,400.00 | |
| 2/26/2014 | Andrew Ashe | VP | Sell | 2,723 | $10.10 | $27,502.30 | |
| 12/5/2013 | Thomas Kempner | Director | Sell | 400,000 | $8.37 | $3,348,000.00 | |
| 8/13/2013 | Andrew Ashe | VP | Sell | 32,500 | $4.30 | $139,750.00 | |
| 5/16/2013 | Marc D Kozin | Director | Buy | 22,971 | $2.46 | $56,508.66 | |
| 2/25/2013 | George V Migausky | CFO | Sell | 4,275 | $3.28 | $14,022.00 | |
| 2/25/2013 | Ivana Magovcevic | COO | Sell | 4,015 | $3.24 | $13,008.60 | |
(Data available from 1/1/2013 forward)
Headline Trends for Dyax Corp. (NASDAQ:DYAX)
Latest Headlines for Dyax Corp. (NASDAQ:DYAX)
| Source: |
|
Dyax Corp. (DYAX) Chart for Friday, September, 22, 2017
